HC Wainwright Forecasts Strong Price Appreciation for Dyne Therapeutics (NASDAQ:DYN) Stock

Dyne Therapeutics (NASDAQ:DYN) had its price target boosted by research analysts at HC Wainwright from $46.00 to $60.00 in a research report issued to clients and investors on Monday, MarketBeat.com reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s price target suggests a potential upside of 225.38% from the company’s previous close. HC Wainwright also issued estimates for Dyne Therapeutics’ FY2029 earnings at $1.56 EPS.

Other equities research analysts also recently issued research reports about the stock. Evercore ISI reissued an “outperform” rating and set a $38.00 price objective on shares of Dyne Therapeutics in a research report on Thursday, November 6th. JPMorgan Chase & Co. cut their price target on Dyne Therapeutics from $18.00 to $17.00 and set a “neutral” rating for the company in a report on Friday, November 14th. Sanford C. Bernstein restated a “market perform” rating and issued a $21.00 price target on shares of Dyne Therapeutics in a research report on Tuesday, November 25th. Oppenheimer lowered their price objective on Dyne Therapeutics from $13.00 to $11.00 and set a “market perform” rating on the stock in a research report on Wednesday, November 12th. Finally, Royal Bank Of Canada boosted their price objective on Dyne Therapeutics from $23.00 to $30.00 and gave the company an “outperform” rating in a research note on Thursday, November 6th. Four analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $36.71.

Dyne Therapeutics Price Performance

Shares of NASDAQ:DYN opened at $18.44 on Monday. The firm’s 50 day moving average price is $18.77 and its 200-day moving average price is $14.14. Dyne Therapeutics has a twelve month low of $6.36 and a twelve month high of $28.96. The company has a quick ratio of 13.47, a current ratio of 13.47 and a debt-to-equity ratio of 0.14. The stock has a market capitalization of $2.63 billion, a PE ratio of -5.04 and a beta of 1.30.

Dyne Therapeutics (NASDAQ:DYN) last announced its earnings results on Wednesday, November 5th. The company reported ($0.76) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.81) by $0.05. Equities research analysts expect that Dyne Therapeutics will post -3.44 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in DYN. RA Capital Management L.P. raised its position in shares of Dyne Therapeutics by 52.2% during the first quarter. RA Capital Management L.P. now owns 9,714,392 shares of the company’s stock valued at $101,613,000 after buying an additional 3,333,248 shares during the last quarter. Adage Capital Partners GP L.L.C. purchased a new position in Dyne Therapeutics during the second quarter valued at $30,378,000. Braidwell LP increased its holdings in Dyne Therapeutics by 431.6% in the 1st quarter. Braidwell LP now owns 3,621,344 shares of the company’s stock valued at $37,879,000 after acquiring an additional 2,940,162 shares during the last quarter. Marshall Wace LLP lifted its stake in Dyne Therapeutics by 572.9% in the 3rd quarter. Marshall Wace LLP now owns 3,013,377 shares of the company’s stock worth $38,119,000 after purchasing an additional 2,565,570 shares in the last quarter. Finally, Vanguard Group Inc. lifted its stake in Dyne Therapeutics by 27.6% in the 3rd quarter. Vanguard Group Inc. now owns 9,760,414 shares of the company’s stock worth $123,469,000 after purchasing an additional 2,109,257 shares in the last quarter. 96.68% of the stock is currently owned by institutional investors.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.